FLT3 Inhibitors Trigger Ferroptosis, Revealing New Weakness in Acute Myeloid Leukemia

Researchers at Baylor College of Medicine have discovered a new mechanism showing how FLT3 inhibitor drugs work against acute myeloid leukemia (AML) by triggering ferroptosis, a form of cell death. This breakthrough, published in Nature Cell Biology, identifies a previously unknown vulnerability in AML that could lead to more effective treatments. The finding is significant because it may allow doctors to target cancer cells while minimizing damage to healthy cells, improving outcomes for AML patients. This discovery opens the door to developing novel therapeutic strategies that exploit this cellular weakness in leukemia.